-
High quality, low risk: record number of Japanese in Premier League
-
Asian Games chiefs hold talks as participant numbers balloon
-
Stocks edge higher as oil drops on fresh Mideast hopes
-
Too small for fries: drought shrinks Belgian potatoes
-
Pakistan's girls fight for their place in the boxing ring
-
Drought-hit Danube gives way to fossil hunt in Bulgaria
-
Five things to know about Anthropic ahead of Wall Street debut
-
Julia Curlee, CIA officer fired by White House for being transgender
-
Social media use on the rise among Australian under-16s after ban: data
-
Fave or flop? A guide to gauging video game success
-
Instagram chief admits touting teen safety tool while omitting it was barely used
-
Williams-Alcaraz fall in US Open mixed quarter-finals
-
'Final Fantasy', 'The Witcher' in spotlight at Europe gaming bash
-
Mark Carney, the former central banker who said 'no' to Trump
-
Syrian Kurdish leader dissolves force that spearheaded jihadist fight
-
Segner out of South Africa tour as New Zealand injuries pile up
-
Trump raises prospect of demolishing iconic Kennedy Center
-
Meta knew teen safety tools were ineffective, witnesses testify
-
PGA Tour to end in two-week matchplay showdown from 2028: CEO
-
Williams and Alcaraz win opener at US Open mixed doubles
-
United States of Dolly: how a country queen bridged America's divide
-
Man Utd's Fernandes crowned PFA player of the year
-
PGA chief says 'no current plans' for LIV stars to return
-
Dolly Parton: quotes on life, love and music
-
Golf giant Callaway apologizes after ad sparks outcry
-
Brazil fines TikTok $30 mn in 'powerful signal' over child safety
-
Ioane stars as New Zealand recover to beat Johannesburg Lions
-
Cameroon's Baleba joins as Man Utd boost midfield options
-
Ukrainians seeking beauty in a bomb-scarred city
-
US country music legend Dolly Parton dies at 80
-
Dolly Parton: Country music's dolled up but deserving queen
-
Kolisi fit to captain South Africa against New Zealand
-
US robotaxi firm Waymo plans to launch in Germany
-
Volkswagen workers boo boss during speech on job cuts
-
'Here to win': Xavi vows to restore pride in Dutch football
-
Djokovic, Sabalenka tumble out of US Open mixed doubles
-
Cameroon's Baleba joins as Man United boost midfield options
-
CIA director Ratcliffe visits Moscow: US media
-
'Shocking' book about Putin's private life wins French literary prize
-
Trump threatens to rename Lake Ontario as 'Lake America'
-
Pogacar storms to Vuelta a Espana stage four solo triumph
-
'Here to win': Xavi vows to restore pride to Dutch football
-
Canada unveils counter-tariffs of 15-50% on US goods
-
Canada unveils counter tariffs of 15% to 50% on US goods
-
Volkswagen boss braces German workers for more job cuts
-
Spain moves to speed up return of migrants stranded in Ceuta
-
Olympic champion Brignone to undergo new knee operation
-
At least a quarter of NFL players may get brain disease: study
-
The summer climate change became scorching reality for Europe
-
Iranians queue for petrol after US announces new sanctions
Brazilian ritual root gets second life as potential anti-depressant
Long used in Indigenous Brazilian rituals, the jurema preta plant, which contains a potent psychedelic, is gaining ground as a potential treatment for depression.
At street stalls where medicinal herbs are sold, customers can buy the plant's root which contains dimethyltryptamine (DMT), a hallucinogenic substance that researchers say could be used to alleviate symptoms.
Following instructions he found on the internet, Guaracy Carvajal extracted DMT at home in 2016 from roots he bought on the street.
The 31-year-old software programmer, who had tried various treatment for chronic depression he has suffered since adolescence, said the drug makes it "feel like you've solved something in your life."
Physicist Draulio Araujo, who has conducted extensive research on the drug, said "the response is rapid. One day after treatment, (patients) already showed a significant improvement in their depression symptoms."
Yet he also warned that it "is not a magic cure" and that psychedelics "are not for everyone."
As a researcher at the Brain Institute of the Federal University of Rio Grande do Norte, Araujo and his team treated 14 people with the drug for six months.
The patients inhaled vaporized DMT, under medical supervision.
"It's common for our patients to say that something changed, that a key opened something," he said.
His patients also received psychological therapy, and some continued with conventional pharmaceutical drugs.
Neuroscientist Fernanda Palhano-Fontes, also of the Brain Institute, said "we have patients who improve significantly, others who don't improve at all."
Araujo's findings were published in the scientific journal Nature in April. In 2024, he published another study with promising results in the journal Psychedelic Medicine.
As for Carvajal, who stopped using jurema preta some time ago, he said the drug really allows a person to "start to have a lighter life."
It helped him get through a time when he was in "a state of questioning myself" about "work, day-to-day life," he said.
- Spiritual channels -
Brazil occupies a fairly prominent place in DMT research due to the substance's prominence in society, Araujo said.
While there is no ban on the cultivation or possession of jurema, which is also known as Mimosa tenuiflora, consumption of DMT is prohibited, except for religious and scientific use.
Jurema's roots are combined with other plants in a wine-like beverage that is consumed at rituals that include dancing and drums, part of Indigenous tradition in northeast Brazil where the plant grows.
"It's not hallucination," said Joyce Souza, a young woman attending a jurema ceremony in Planaltina, on the outskirts of Brasília.
"My spiritual channels become more accessible, I can communicate better with myself," Souza said.
Gathered in a house courtyard and dressed in white, the group of mostly novices waited for more seasoned practitioners to enter a trance and bring messages from ancient spirits.
Meanwhile, back in the lab, Araujo is hoping to expand his DMT research to a study of 100 patents.
"Let's say that in five years we'll have... a clear picture on when it will reach a real clinical setting," he said.
Ch.Campbell--AT